Genocea Biosciences (GNCA) Completes GEN-003 Phase 2 Enrollment
Tweet Send to a Friend
Genocea Biosciences (NASDAQ: GNCA) reported that it has completed enrollment in its Phase 2 dose optimization clinical trial for GEN-003 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE